Literature DB >> 2417653

Comparison of clinical scores and acute phase proteins in the assessment of acute Crohn's disease.

S H Pettit, I B Holbrook, M H Irving.   

Abstract

Fifty-two patients with Crohn's disease have been assessed using acute phase proteins and a scoring system. Thirty-nine underwent operation and intra-abdominal abscesses were found in seventeen. Both scores and acute phase proteins have been shown to reflect inflammation due to secondary sepsis in addition to that from active Crohn's disease. The scores were higher, and acute phase changes greater, in patients with sepsis than those without. By choosing a threshold for each variable that excludes patients without sepsis it has been found that a score greater than 181, ESR greater than 45 mm/h, CRP greater than 33 mg/l, orosomucoid greater than 1.8 g/l and albumin less than 26.7 g/l identify sepsis with a specificity greater than 95 per cent and sensitivity greater than 35 per cent. Over 70 per cent of patients with abscesses exceeded one or more of these thresholds. We believe that operative management should be strongly considered if one or more of these criteria are positive as such patients have a greater than 90 per cent chance of having an intra-abdominal abscess. This will prevent these abscesses eroding into adjacent viscera or to the surface with resulting fistula formation.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2417653     DOI: 10.1002/bjs.1800721226

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  2 in total

1.  Faecal diversion for Crohn's colitis: a model to study the role of the faecal stream in the inflammatory process.

Authors:  M C Winslet; A Allan; V Poxon; D Youngs; M R Keighley
Journal:  Gut       Date:  1994-02       Impact factor: 23.059

2.  Ascorbic acid absorption in Crohn's disease. Studies using L-[carboxyl-14C]ascorbic acid.

Authors:  S H Pettit; J L Shaffer; C W Johns; R J Bennett; M H Irving
Journal:  Dig Dis Sci       Date:  1989-04       Impact factor: 3.199

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.